当PD-1单抗的年销售额突破百亿美元时，全球医药界正把目光投向更艰难的战场——实体瘤细胞治疗。2024年ASCO会议数据显示，全球在研CAR-T项目中针对实体瘤的仅占12.7%，而其中进入临床II期的不足3%。在这个背景下，易慕峰IMC001新增适应症获批的消息犹如一剂强心针：这款靶向EpCAM的CAR-T产品不仅完成中美双报，更将适应症从消化系统肿瘤拓展至泛上皮源性实体瘤，其90%的疾病控制率和 ...

BioAtla is extending its runway beyond key clinical readouts in 1H 2026 by restructuring and realigning resources, which ...

Q4 2024 Earnings Call Transcript March 27, 2025 BioAtla, Inc. beats earnings expectations. Reported EPS is $-0.285, ...

Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ETCompany ParticipantsBruce Mackle - LifeSci Advisors, ...

BioAtla is laying off 30% of staff as the biotech searches for partners for some of its conditionally active biologic (CAB) ...

Reports cash and cash equivalents as of December 31, were $49M , compared to $111.5M as of December 31, 2023. We expect that cost reductions ...

Investing.com — BioAtla Inc. (NASDAQ: BCAB)公布了2024年第四季度财务业绩，重点展示了战略性成本削减和临床项目的进展。在交易时段内，该公司股价上涨4.81%至0.39美元，反映了投资者的乐观情绪，尽管在盘后交易中略微下跌0.71%。

In March 2025, Merck Sharp & Dohme LLC announced a study are to learn if people who receive V940 and pembrolizumab are alive ...

Investing.com — 周五，BTIG分析师Justin Zelin调整了BioAtla Inc. (NASDAQ: BCAB )股票的目标价，将其从此前的13.00美元下调至10.00美元，同时维持对该公司股票的买入评级。根据 InvestingPro ...